Literature DB >> 31432289

Three-dimensional echocardiography investigation of the mechanisms of tricuspid annular dilatation.

Valentina Volpato1,2, Victor Mor-Avi1, Federico Veronesi3, Karima Addetia1, Megan Yamat1, Lynn Weinert1, Davide Genovese1, Gloria Tamborini2, Mauro Pepi2, Roberto M Lang4.   

Abstract

Tricuspid annular (TA) size, assessed by 2D transthoracic echocardiography (TTE), has a well-established prognostic value in patients undergoing mitral valve surgery, with TA dilatation triggering simultaneous tricuspid annuloplasty. While TA dilatation is common in patients with dilated atria secondary to atrial fibrillation, little is known about the mechanisms of TA dilatation in patients with sinus rhythm (SR). This study aimed to identify echocardiographic parameters most closely related to the TA size as a potential tool for identification of patients prone to developing TA enlargement. 120 patients with SR underwent clinically indicated TTE, including 30 patients with normal hearts and 90 patients diagnosed with at least one right heart abnormality, defined as: right ventricular (RV) or right atrial (RA) dilatation, ≥ moderate tricuspid regurgitation (TR) and elevated systolic pulmonary artery pressure (sPAP). RA and RV end-diastolic and end-systolic volumes (EDV, ESV) and function were measured using commercial 3D software (TomTec). 3D RV long and short axes were used as surrogate indices of RV shape. Degrees of TR and sPAP were estimated by 2D TTE. 3D TA sizing was performed at end-diastole using 3D custom software. Linear regression analysis was used to identify variables best correlated with TA size, followed by multivariate analysis to identify independent associations. The highest correlations were found between TA area and: RA ESV (r = 0.73; p < 0.01), RV EDV (r = 0.58; p < 0.01), RV end-diastolic long and short axes (r = 0.53, 0.42; both p < 0.01), TR degree (r = 0.40; p < 0.01) and sPAP (r = 0.32; p < 0.01). Multivariate analysis revealed that RA ESV was the only parameter independently associated with TA area (p < 0.05, r = 0.85). In conclusion, RA volume plays an important role in TA dilatation even in patients with normal SR. Understanding of annular remodeling mechanisms could aid in identifying patients at higher risk for TA dilatation, especially those scheduled for mitral valve surgery.

Entities:  

Keywords:  3D echocardiography; 3D volume; Right chambers; Tricuspid annulus; Tricuspid valve

Mesh:

Year:  2019        PMID: 31432289     DOI: 10.1007/s10554-019-01686-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  31 in total

1.  Mid-term results of a randomized trial of tricuspid annuloplasty for less-than-severe functional tricuspid regurgitation at the time of mitral valve surgery†.

Authors:  Matteo Pettinari; Laurent De Kerchove; Siham Lazam; Agnes Pasquet; Bernard Gerber; Jean-Louis Vanoverschelde; Gebrine El-Khoury
Journal:  Eur J Cardiothorac Surg       Date:  2019-05-01       Impact factor: 4.191

2.  Prophylactic tricuspid annuloplasty in patients with dilated tricuspid annulus undergoing mitral valve surgery.

Authors:  Umberto Benedetto; Giovanni Melina; Emiliano Angeloni; Simone Refice; Antonino Roscitano; Cosimo Comito; Riccardo Sinatra
Journal:  J Thorac Cardiovasc Surg       Date:  2012-01-11       Impact factor: 5.209

3.  2017 ESC/EACTS Guidelines for the management of valvular heart disease.

Authors:  Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2017-09-21       Impact factor: 29.983

Review 4.  Anatomy of the Tricuspid Valve, Pathophysiology of Functional Tricuspid Regurgitation, and Implications for Percutaneous Therapies.

Authors:  Nicola Buzzatti; Michele De Bonis; Neil Moat
Journal:  Interv Cardiol Clin       Date:  2017-10-21

5.  Surgical management of secondary tricuspid valve regurgitation: annulus, commissure, or leaflet procedure?

Authors:  Jose L Navia; Edward R Nowicki; Eugene H Blackstone; Nicolas A Brozzi; Daniel E Nento; Fernando A Atik; Jeevanantham Rajeswaran; A Marc Gillinov; Lars G Svensson; Bruce W Lytle
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-14       Impact factor: 5.209

Review 6.  Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management.

Authors:  Avinoam Shiran; Alex Sagie
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

7.  Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction.

Authors:  Todd M Koelling; Keith D Aaronson; Robert J Cody; David S Bach; William F Armstrong
Journal:  Am Heart J       Date:  2002-09       Impact factor: 4.749

8.  Pathogenic structural heart changes in early tricuspid regurgitation.

Authors:  Naohiko Nemoto; John R Lesser; Wesley R Pedersen; Paul Sorajja; Erin Spinner; Ross F Garberich; David M Vock; Robert S Schwartz
Journal:  J Thorac Cardiovasc Surg       Date:  2015-05-08       Impact factor: 5.209

9.  Impact of tricuspid regurgitation on long-term survival.

Authors:  Jayant Nath; Elyse Foster; Paul A Heidenreich
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

10.  3-Dimensional Echocardiographic Analysis of the Tricuspid Annulus Provides New Insights Into Tricuspid Valve Geometry and Dynamics.

Authors:  Karima Addetia; Denisa Muraru; Federico Veronesi; Csaba Jenei; Giacomo Cavalli; Stephanie A Besser; Victor Mor-Avi; Roberto M Lang; Luigi P Badano
Journal:  JACC Cardiovasc Imaging       Date:  2017-11-15
View more
  1 in total

1.  Three-dimensional psychological guidance combined with evidence-based health intervention in patients with liver abscess treated with ultrasound.

Authors:  Ya-Nan Shan; Ying Yu; Yi-Han Zhao; Lian-Lian Tang; Xiao-Min Chen
Journal:  World J Clin Cases       Date:  2022-08-16       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.